A teaser image for PhRMA's Letter to Congress concerning the Inflation Reduction Act of 2022

PhRMA Member Company CEOs sent a letter urging Congress to reject the drug pricing provisions in the Inflation Reduction Act of 2022 and to instead work with all health care stakeholders on a balanced approach that delivers more affordable care for everyone and protects America’s global R&D leadership today and in the future.

A teaser image for PhRMA's Letter to Congress concerning the Inflation Reduction Act of 2022

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.